Tempest Therapeutics
TPST
21 hedge funds and large institutions have $1.44M invested in Tempest Therapeutics in 2026 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 5 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
67% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 3
11% more capital invested
Capital invested by funds: $1.29M → $1.44M (+$146K)
5% less funds holding
Funds holding: 22 → 21 (-1)
7.23% less ownership
Funds ownership: 15.97% → 8.74% (-7.2%)
20% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$814K |
| 2 |
Squarepoint
New York
|
+$51K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$32.7K |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$10K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$1.87K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$54.5K |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
-$18.8K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
-$602 |
| 4 |
Vanguard Global Advisers
Malvern,
Pennsylvania
|
-$276 |
| 5 |
Morgan Stanley
New York
|
-$59 |
TPST Hedge Fund Activity: Q2 2026 in Review
21 of the 8,316 institutional investors tracked by Wall St. Rank reported a position in Tempest Therapeutics (TPST) for Q2 2026, worth a combined $1.44M — up 11% from $1.29M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of TPST and 4 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 5 added.
The largest buyer was Sabby Management, adding an estimated $814K. The largest seller was Fidelity Investments, exiting entirely with an estimated $54.5K sold.
- 21 institutional investors held Tempest Therapeutics (TPST) as of Q2 2026, down from 22 in Q1 2026.
- Funds reported $1.44M of Tempest Therapeutics stock for Q2 2026, up 11% quarter-over-quarter.
- 4 funds opened new Tempest Therapeutics positions in Q2 2026 and 5 closed out, a net change of -1 holder.
- The largest Tempest Therapeutics buyer in Q2 2026 was Sabby Management, an estimated $814K added.
- The largest Tempest Therapeutics seller in Q2 2026 was Fidelity Investments, an estimated $54.5K sold.
Based on aggregated 13F filings for Q2 2026.